BD (Becton, Dickinson and Company) has named Bridget Bagnato as the worldwide president of its Peripheral Intervention business unit, effective November 16. Bagnato will lead the unit's global strategy, operations, and commercial performance from Tempe, Arizona, reporting to Peter Menziuso. With over 27 years at BD and leadership experience across various business units, she is expected to drive innovation and growth in technologies addressing peripheral vascular disease, oncology, and kidney disease. This leadership change aims to advance BD's impact in medical technology and patient care worldwide.
BDX (Becton Dickinson and Co) shares trade at USD 200.18 on Pluang as of Nov 04, 2026 19:01 WIB, up 1.01% for the day. The stock is near its 52-week high of USD 200.42, showing steady investor interest. BDX's market cap stands at $53.98 billion, reflecting its strong position in the health sector.
